ADDF awards $210.

Amicus’ encounter using PCs to stabilize correct proteins folding in Fabry disease provides support that this strategy has the potential to benefit patients. Wustman and his co-workers.’ ‘The grant from the ADDF allows Amicus to expand on the company’s exciting results implicating ganglioside catabolism in both beta-amyloid and tau disease pathways in Alzheimer’s disease,’ stated Dr. Howard Fillit, the ADDF’s Executive Director. ‘This novel approach has the potential to considerably impact the disease at multiple levels.’.. ADDF awards $210,300 to Amicus Therapeutics to judge PCs for treating Alzheimer’s disease The Alzheimer’s Drug Discovery Basis announced today that it has awarded a grant of $210,300 to Amicus Therapeutics to judge small-molecule, orally shipped pharmacological chaperone substances as a novel approach for dealing with Alzheimer’s disease.Klegerman The ATHENA project includes top capabilities and researchers in this pioneering field of research. The project components are divided the following: Furthermore to leading and coordinating the project, Iyer is directing work on the lung and kidney organ as well as step-wise integration and validation out of all the organs in the ATHENA perfusion system – all of which will end up being executed at LANL. Wikswo and his VIIBRE group are building the hardware platform that 'runs' and monitors the fitness of the entire system, while the 1st organ, the liver construct, which was tested in the ATHENA platform at VIIBRE recently, is being developed by Katrin Zeilinger, mind of the Bioreactor Group, Experimental Surgery, and colleagues at Charit – Universit-tsmedizin, Berlin, Germany.